"peptide","aka","url","pcac_status","legal_to_compound_today","fda_approved_drug","evaluated_use","human_clinical_data","wada_status","evaluation_track","notes","source_titles","source_urls","last_verified"
"BPC-157","","https://www.trycora.io/peptides/bpc-157/","Recommended for the 503A bulks list, 8-6-1, 2026-07-23 (advisory recommendation, against FDA staff)","No — not on the FDA 503A bulks list; no final rule","No","Studied for tissue and gut repair; the use FDA evaluated was ulcerative colitis","Limited — a single small, decades-old abstract; FDA staff cited insufficient human data","Not addressed in the sources reviewed","PCAC evaluated 2026-07-23","Recommended 8-6-1 on July 23, 2026 for ulcerative colitis, over FDA staff's position that the human data is insufficient — the only human evidence located in the sources reviewed is a single small, decades-old abstract. Advisory recommendation only; being recommended for the 503A bulks list would permit compounding under a patient-specific prescription and is not the same as being an FDA-approved, FDA-reviewed drug. FDA career scientists recommended against listing, and the FDA has not made a final decision. It is not legal to compound today.","FDA — Pharmacy Compounding Advisory Committee (PCAC) | FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A | FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and uses evaluated) | RAPS — FDA advisory committee backs two controversial peptides, 2026-07-23 | Reuters — FDA staff highlights peptide risks, says little evidence of benefits, 2026-06-30 | Reuters — FDA advisers back first four of seven unapproved peptides under review for looser rules, 2026-07-23","https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee; https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca; https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026; https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html; https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/; https://www.reuters.com/legal/litigation/us-fda-advisers-weigh-restrictions-seven-peptides-industry-presses-expansion-2026-07-23/","2026-07-25"
"KPV","","https://www.trycora.io/peptides/kpv/","Recommended for the 503A bulks list, 8-6-1, 2026-07-23 (advisory recommendation, against FDA staff)","No — not on the FDA 503A bulks list; no final rule","No","Fragment of alpha-MSH; the uses FDA evaluated were wound healing and inflammatory conditions","None found — no human clinical trials located; FDA staff cited absence of human data","Not addressed in the sources reviewed","PCAC evaluated 2026-07-23","Recommended 8-6-1 on July 23, 2026 for wound healing and inflammatory conditions, over FDA staff's position that no human clinical trials of KPV could be located. Advisory recommendation only; being recommended for the 503A bulks list would permit compounding under a patient-specific prescription and is not the same as being an FDA-approved, FDA-reviewed drug. FDA career scientists recommended against listing, and the FDA has not made a final decision. It is not legal to compound today.","FDA — Pharmacy Compounding Advisory Committee (PCAC) | FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A | FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and uses evaluated) | RAPS — FDA advisory committee backs two controversial peptides, 2026-07-23 | Reuters — FDA staff highlights peptide risks, says little evidence of benefits, 2026-06-30 | Reuters — FDA advisers back first four of seven unapproved peptides under review for looser rules, 2026-07-23","https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee; https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca; https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026; https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html; https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/; https://www.reuters.com/legal/litigation/us-fda-advisers-weigh-restrictions-seven-peptides-industry-presses-expansion-2026-07-23/","2026-07-25"
"TB-500","","https://www.trycora.io/peptides/tb-500/","Recommended for the 503A bulks list, 8-6-1, 2026-07-23 (advisory recommendation, against FDA staff)","No — not on the FDA 503A bulks list; no final rule","No","Thymosin beta-4 fragment; the use FDA evaluated was wound healing","None found — no human clinical studies located; FDA staff cited absence of human data","Prohibited (WADA)","PCAC evaluated 2026-07-23","Recommended 8-6-1 on July 23, 2026 for wound healing, over FDA staff's position that no human clinical studies could be located; TB-500 is also prohibited by the World Anti-Doping Agency. Advisory recommendation only; being recommended for the 503A bulks list would permit compounding under a patient-specific prescription and is not the same as being an FDA-approved, FDA-reviewed drug. FDA career scientists recommended against listing, and the FDA has not made a final decision. It is not legal to compound today.","FDA — Pharmacy Compounding Advisory Committee (PCAC) | FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A | FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and uses evaluated) | RAPS — FDA advisory committee backs two controversial peptides, 2026-07-23 | Reuters — FDA staff highlights peptide risks, says little evidence of benefits, 2026-06-30 | Reuters — FDA advisers back first four of seven unapproved peptides under review for looser rules, 2026-07-23","https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee; https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca; https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026; https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html; https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/; https://www.reuters.com/legal/litigation/us-fda-advisers-weigh-restrictions-seven-peptides-industry-presses-expansion-2026-07-23/","2026-07-25"
"MOTS-c","","https://www.trycora.io/peptides/mots-c/","Recommended for the 503A bulks list, 7-5, 2026-07-23 (advisory recommendation, against FDA staff)","No — not on the FDA 503A bulks list; no final rule","No","Mitochondrial-derived peptide; the uses FDA evaluated were obesity and osteoporosis","None found — no human clinical data located","Prohibited (WADA)","PCAC evaluated 2026-07-23","The only peptide in the set whose FDA-evaluated use includes obesity; it is not an alternative to a prescribed GLP-1 medication. Recommended 7-5 on July 23, 2026 for obesity and osteoporosis, on a smaller panel tally than the 8-6-1 recorded for BPC-157/KPV/TB-500 — the margin was two votes in both cases. Advisory recommendation only; being recommended for the 503A bulks list would permit compounding under a patient-specific prescription and is not the same as being an FDA-approved, FDA-reviewed drug. FDA career scientists recommended against listing, and the FDA has not made a final decision. It is not legal to compound today.","FDA — Pharmacy Compounding Advisory Committee (PCAC) | FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A | FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and uses evaluated) | Reuters — FDA staff highlights peptide risks, says little evidence of benefits, 2026-06-30 | Reuters — FDA advisers back first four of seven unapproved peptides under review for looser rules, 2026-07-23","https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee; https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca; https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026; https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/; https://www.reuters.com/legal/litigation/us-fda-advisers-weigh-restrictions-seven-peptides-industry-presses-expansion-2026-07-23/","2026-07-25"
"Emideltide","DSIP","https://www.trycora.io/peptides/emideltide-dsip/","Rejected by PCAC — voted against inclusion on the 503A bulks list, 6-7-1, 2026-07-24 (the committee's only rejection)","No — not on the FDA 503A bulks list; no final rule","No","Delta sleep-inducing peptide (DSIP); the uses FDA evaluated were opioid withdrawal, chronic insomnia, and narcolepsy","None found — FDA cited a lack of safety and efficacy data and inadequate characterization; a witness noted the last study was roughly 30 years old","Not addressed in the sources reviewed","PCAC evaluated 2026-07-24","PCAC voted against adding Emideltide to the 503A bulks list, aligning with FDA staff, who cited a lack of safety and efficacy data, inadequate characterization, and existing FDA-approved therapies for the proposed uses. Not an FDA final decision either way.","FDA — Pharmacy Compounding Advisory Committee (PCAC) | FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A | FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and uses evaluated) | Reuters — FDA staff highlights peptide risks, says little evidence of benefits, 2026-06-30 | RAPS — FDA advisory committee backs two more peptides, rejects one for compounding list, 2026-07-24","https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee; https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca; https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026; https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/; https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html","2026-07-25"
"Semax","","https://www.trycora.io/peptides/semax/","Recommended for the 503A bulks list, 8-5, 2026-07-24 (advisory recommendation, against FDA staff)","No — not on the FDA 503A bulks list; no final rule","No","The uses FDA evaluated were cerebral ischemia, migraine, and trigeminal neuralgia","Not detailed in the sources reviewed","Not addressed in the sources reviewed","PCAC evaluated 2026-07-24","Recommended 8-5 on July 24, 2026 for cerebral ischemia, migraine and trigeminal neuralgia. Human clinical data for Semax was not detailed in the sources reviewed, so this entry asserts none. Advisory recommendation only; being recommended for the 503A bulks list would permit compounding under a patient-specific prescription and is not the same as being an FDA-approved, FDA-reviewed drug. FDA career scientists recommended against listing, and the FDA has not made a final decision. It is not legal to compound today.","FDA — Pharmacy Compounding Advisory Committee (PCAC) | FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A | FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and uses evaluated) | Reuters — FDA staff highlights peptide risks, says little evidence of benefits, 2026-06-30 | RAPS — FDA advisory committee backs two more peptides, rejects one for compounding list, 2026-07-24","https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee; https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca; https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026; https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/; https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html","2026-07-25"
"Epitalon","","https://www.trycora.io/peptides/epitalon/","Recommended for the 503A bulks list, 7-5-1, 2026-07-24 (advisory recommendation, against FDA staff)","No — not on the FDA 503A bulks list; no final rule","No","The use FDA evaluated was insomnia","None found — FDA cited no published efficacy data for the proposed insomnia use, plus immunogenicity and impurity risks","Not addressed in the sources reviewed","PCAC evaluated 2026-07-24","Recommended 7-5-1 on July 24, 2026 for insomnia, over FDA staff's position that there is no published efficacy data for the proposed insomnia use, alongside immunogenicity and impurity risks. Advisory recommendation only; being recommended for the 503A bulks list would permit compounding under a patient-specific prescription and is not the same as being an FDA-approved, FDA-reviewed drug. FDA career scientists recommended against listing, and the FDA has not made a final decision. It is not legal to compound today.","FDA — Pharmacy Compounding Advisory Committee (PCAC) | FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A | FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and uses evaluated) | Reuters — FDA staff highlights peptide risks, says little evidence of benefits, 2026-06-30 | RAPS — FDA advisory committee backs two more peptides, rejects one for compounding list, 2026-07-24","https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee; https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca; https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026; https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/; https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html","2026-07-25"